Denatonium acetate
Denatonium acetate (ARD-101) is an experimental anti-obesity drug that is a prodrug of the bitter compound denatonium, which is thought to be an agonist of the bitter-sensing type 2 taste receptors (TAS2R). It is hoped to activate the TAS2R receptors in the gut.[1][2] It is tested in healthy adults[3] and people with Prader-Willi syndrome.[4]
References[edit]
- ^ Dutton, Gail (1 February 2022). "Bitter Taste Receptors Represent a Therapeutic Sweet Spot: Stimulating bitter taste receptors, the body's early warning system for toxic substances, can fight obesity and inflammation". Genetic Engineering & Biotechnology News. 42 (2): 16–17. doi:10.1089/gen.42.02.06. S2CID 246841111.
- ^ Senior, Melanie (1 June 2023). "After GLP-1, what's next for weight loss?". Nature Biotechnology. 41 (6): 740–743. doi:10.1038/s41587-023-01818-4. ISSN 1546-1696. PMID 37280436. S2CID 259152649.
- ^ Niethammer, Andreas G.; Zheng, Zhenhuan; Timmer, Anjuli; Lee, Tien-Li (August 2022). "First-in-Human Evaluation of Oral Denatonium Acetate (ARD-101), a Potential Bitter Taste Receptor Agonist: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial in Healthy Adults". Clinical Pharmacology in Drug Development. 11 (8): 997–1006. doi:10.1002/cpdd.1100. ISSN 2160-7648. PMID 35509219. S2CID 248525889.
- ^ Hedstrom, Susan. "ARD-101 as a Potential Treatment for PWS". www.fpwr.org. Retrieved 5 December 2023.